CounterX TherapeuticsCounterX TherapeuticsCounterX Therapeutics
  • Home
  • About
  • Platform
  • Pipeline
    • CTRX 101
    • Publications
  • Team
  • News
  • Contact

Search Posts

About Us

Lorem ipsum dolor sit amet, consectetur adipisc glelit, sed do eiusmod tempor incididunt .ut labo et dolore magna aliqua.

Blog Categories

  • Press Release (1)
  • Publications (9)

Recent Posts

October 29, 2025

CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model

by pjwcreative
Post placeholder image
October 10, 2025

An anti-fentanyl monoclonal antibody reverses fentanyl-induced apnea in pigs

by pjwcreative
Post placeholder image
January 21, 2025

Psychopharmacology:  A humanized monoclonal antibody attenuates fentanyl self-administration and reverses and prevents fentanyl-induced ventilatory depression in rhesus monkeys 

by pjwcreative
Post placeholder image
October 7, 2024

ACS Omega: Structure-Based Engineering of Monoclonal Antibodies for Improved Binding to Counteract the Effects of Fentanyl and Carfentanil

by pjwcreative
Post placeholder image
July 17, 2024

The Journal of Immunology: Monoclonal Antibodies Engineered with Fc Region Mutations to Extend Protection against Fentanyl Toxicity

by pjwcreative
Post placeholder image
March 1, 2023

Expert Opinion Investigational Drugs: The potential role of opioid vaccines and monoclonal antibodies in the opioid overdose crisis

by pjwcreative

Recent Comments

No comments to show.

Tags

Post placeholder image
July 17, 2024 in Publications

The Journal of Immunology: Monoclonal Antibodies Engineered with Fc Region Mutations to Extend Protection against Fentanyl Toxicity

pjwcreative 0 Like Post Comments Off on The Journal of Immunology: Monoclonal Antibodies Engineered with Fc Region Mutations to Extend Protection against Fentanyl Toxicity

Khaimraj A, Baehr CA, Hicks D, Raleigh MD, Pravetoni M. J Immunol. 2024 Sep 1;213(5):663-668. doi: 10.4049/jimmunol.2400170. PMID: 39018496

Read More
  • Follow Us
  • Contact Us

©2025 CounterX Therapeutics. All Rights Reserved.